Neuroendocrine Tumors
17 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Neoplasms, Neoplasms, Germ Cell and Embryonal
Narrower: Carcinoid Tumor 2, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Pheochromocytoma 2
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 61Cu-NODAGA-LM3 + Comparator for neuroendocrine tumors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 68-Gallium DOTATATE for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atezolizumab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabozantinib for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabozantinib + NIVOLUMAB for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lurbinectedin for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LUTETIUM OXODOTREOTIDE LU-177 for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pheochromocytoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pheochromocytoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab + lenvatinib for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sbrt for neuroendocrine tumors | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Selpercatinib for carcinoma, medullary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tarlatamab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Temozolomide for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumors | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.